Omidria acquisition, FDA clearances lead December news
Click Here to Manage Email Alerts
The top pieces of news in ophthalmology in December include acquisitions and FDA clearances.
Read the best-performing pieces of ophthalmology coverage from December below.
Rayner Surgical to acquire Omidria in deal valued at more than $1 billion
Omeros will sell Omidria to Rayner Surgical Group Limited in a transaction valued at more than $1 billion, according to a press release from Omeros. Read more.
FDA clears TearCare system for treatment of meibomian gland dysfunction
The TearCare system has received 510(k) clearance from the FDA for the treatment of meibomian gland dysfunction, according to a press release from Sight Sciences. Read more.
BLOG: Tunable IOLs will end exchanges
Through their careers, most cataract surgeons become extremely comfortable with and adept at performing phacoemulsification, removing even the most challenging lenses and placing lens implants with little stress. Read more.
Harrow Health acquires US rights to four eye drops
Harrow Health acquired the United States commercialization rights to four ophthalmic drops from Novartis, according to a press release. Read more.
IOL exchange all about setting patient expectations, determining plan of action
With modern calculations and state-of-the-art lenses, IOL exchange is not regularly needed. According to Healio/OSN Section Editor Uday Devgan, MD, it is downright rare, at least in his practice. Read more.
Collapse
Read more about
Click Here to Manage Email Alerts